Oncology1 year ago
New Targeted Therapy for Non-Small Cell Lung Cancer Extends Life for Patients With Genetic Mutation
The immunotherapy drug, durvalumab, has been the norm of care for patients with stage III non-little cell lung cancer(NSCLC) to further develop endurance, when recommended after...
